Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b study of the safety, efficacy and pharmacokinetics of telaprevir in combination with peginterferon alpha 2a + ribavirin in liver transplant patients with recurrent hepatitis C genotype 1 (REFRESH)

Trial Profile

Phase 2b study of the safety, efficacy and pharmacokinetics of telaprevir in combination with peginterferon alpha 2a + ribavirin in liver transplant patients with recurrent hepatitis C genotype 1 (REFRESH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REFRESH
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 16 May 2013 Interim data, from the first 23 patients, presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 16 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top